Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2 seropositive persons during early HIV-1 infection

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 734-738

  Nina Kim, H ^a,k   Wang, Jing ^c   Hughes, James ^c   Coombs, Robert ^a   Sanchez, Jorge ^g   Reid, Stewart ^d,h   Delany Moretlwe, Sinead ⁱ   Cowan, Frances ^j   Fuchs, Jonathan ^e   Eshleman, Susan H ^f   Khaki, Leila ^c   McMahon, Moira A ^f   Siliciano, Robert F ^f   Wald, Anna ^a,c   Celum, Connie ^a,b  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^e SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Asociacion Civil Impacta Salud y Educacion (IMPACTA)   (United States)

^h CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ISOLEUCINE; RNA DIRECTED DNA POLYMERASE; VALINE; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; VIRUS MUTATION;

ACYCLOVIR; ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77955695101     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655662     Document Type: Article

References (15)

1. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11(suppl 1):24A-35A.
2. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
3. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620.
4. Lyles RH, Munoz A, Yamashita TE, et al; for the Multicenter AIDS Cohort Study. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J Infect Dis 2000; 181:872-880.
5. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-579.
6. Barbour JD, Sauer MM, Sharp ER, et al. HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts. PLoS One 2007; 2:e1080.
7. Cachay ER, Frost SD, Richman DD, Smith DM, Little SJ. Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection. J Infect Dis 2007; 195:1270-1277.
8. Gray RH, Li X,Wawer MJ, et al. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J Infect Dis 2004; 189:1209-1215.
9. Lisco A, Vanpouille C, Tchesnokov EP, et al. Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues. Cell Host Microbe 2008; 4:260-270.
10. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:31289-31293.
11. Tchesnokov EP, Obikhod A, Massud I, et al. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. J Biol Chem 2009; 284:21496-21504.
12. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
13. Serwadda D, Gray RH, Sewankambo NK, et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003; 188:1492-1497.
14. McMahon MA, Siliciano JD, Kohli RM, Siliciano RF. Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs. AIDS 2010; 24:319-323.
15. Fuchs J, Celum C, Wang J, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis 2010; 201:1164-1168.